Characterization of Clostridioides difficile Isolates Available through the CDC & FDA Antibiotic Resistance Isolate Bank

Ashley Paulick; Michelle Adamczyk; Karen Anderson; Nick Vlachos; María-José Machado; Gillian McAllister; Lauren Korhonen; Alice Y Guh; Alison Laufer Halpin; J Kamile Rasheed; Maria Karlsson; Joseph D Lutgring; Amy S Gargis; Emerging Infections Program Clostridioides difficile Pathogen Group

doi:10.1128/MRA.01011-20

Characterization of Clostridioides difficile Isolates Available through the CDC & FDA Antibiotic Resistance Isolate Bank

Microbiol Resour Announc. 2021 Jan 7;10(1):e01011-20. doi: 10.1128/MRA.01011-20.

Authors

Affiliations

¹ Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
² Goldbelt C6, LLC, Chesapeake, Virginia, USA.
³ Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA AGargis@cdc.gov.

Abstract

Thirty Clostridioides difficile isolates collected in 2016 through the Centers for Disease Control and Prevention Emerging Infections Program were selected for reference antimicrobial susceptibility testing and whole-genome sequencing. Here, we present the genetic characteristics of these isolates and announce their availability in the CDC & FDA Antibiotic Resistance Isolate Bank.